137 related articles for article (PubMed ID: 8068876)
1. Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35).
Hebert LA; Birmingham DJ; Dillon JJ; Cosio FG; Shen XP
J Am Soc Nephrol; 1994 Apr; 4(10):1786-91. PubMed ID: 8068876
[TBL] [Abstract][Full Text] [Related]
2. Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.
Ohi H; Tamano M; Sudo S; Okada N
Am J Kidney Dis; 2003 Jan; 41(1):179-85. PubMed ID: 12500235
[TBL] [Abstract][Full Text] [Related]
3. Low number of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinemia, systemic lupus erythematosus and rheumatoid arthritis: relationship with disease activity, anticardiolipin antibodies, complement activation and therapy.
Corvetta A; Pomponio G; Bencivenga R; Luchetti MM; Spycher M; Spaeth PJ; Danieli G
J Rheumatol; 1991 Jul; 18(7):1021-5. PubMed ID: 1833542
[TBL] [Abstract][Full Text] [Related]
4. CR1 on erythrocytes of Brazilian systemic lupus erythematosus patients: the influence of disease activity on expression and ability of this receptor to bind immune complexes opsonized with complement from normal human serum.
Marzocchi-Machado CM; Alves CM; Azzolini AE; Polizello AC; Carvalho IF; Lucisano-Valim YM
J Autoimmun; 2005 Dec; 25(4):289-97. PubMed ID: 16289666
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of C3b receptor (CR1) on erythrocytes of patients with systemic lupus erythematosus contrasts with its normal expression in other systemic diseases and does not correlate with the occurrence or severity of SLE nephritis.
Jouvin MH; Wilson JG; Bourgeois P; Fearon DT; Kazatchkine MD
Complement; 1986; 3(2):88-96. PubMed ID: 2945697
[TBL] [Abstract][Full Text] [Related]
6. No quantitative relationship between CR1 and Lutheran expression on erythrocytes: In(Lu) gene product is not a common regulator of CR1 expression on erythrocytes.
Oudin S; Lepennec PY; Dervillez X; Tonye-Libyh M; Tabary T; Philbert F; Bougy F; Reveil B; Pennaforte JL; Rouger P; Cohen JH
Exp Clin Immunogenet; 1999; 16(2):72-80. PubMed ID: 10343158
[TBL] [Abstract][Full Text] [Related]
7. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
8. Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.
Birmingham DJ; Gavit KF; McCarty SM; Yu CY; Rovin BH; Nagaraja HN; Hebert LA
Clin Exp Immunol; 2006 Feb; 143(2):274-80. PubMed ID: 16412051
[TBL] [Abstract][Full Text] [Related]
9. Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients.
Kisserli A; Schneider N; Audonnet S; Tabary T; Goury A; Cousson J; Mahmoudi R; Bani-Sadr F; Kanagaratnam L; Jolly D; Cohen JH
Immunobiology; 2021 May; 226(3):152093. PubMed ID: 34022670
[TBL] [Abstract][Full Text] [Related]
10. Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE).
Cohen JH; Lutz HU; Pennaforte JL; Bouchard A; Kazatchkine MD
Clin Exp Immunol; 1992 Mar; 87(3):422-8. PubMed ID: 1531948
[TBL] [Abstract][Full Text] [Related]
11. A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b.
Birmingham DJ; Chen W; Liang G; Schmitt HC; Gavit K; Nagaraja HN
Immunology; 2003 Apr; 108(4):531-8. PubMed ID: 12667215
[TBL] [Abstract][Full Text] [Related]
12. The C3b/C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms.
Cohen JH; Atkinson JP; Klickstein LB; Oudin S; Subramanian VB; Moulds JM
Mol Immunol; 1999; 36(13-14):819-25. PubMed ID: 10698335
[TBL] [Abstract][Full Text] [Related]
13. Complement receptor 1 (CD35) on human reticulocytes: normal expression in systemic lupus erythematosus and HIV-infected patients.
Lach-Trifilieff E; Marfurt J; Schwarz S; Sadallah S; Schifferli JA
J Immunol; 1999 Jun; 162(12):7549-54. PubMed ID: 10358211
[TBL] [Abstract][Full Text] [Related]
14. Hind III genomic polymorphism of the C3b receptor (CR1) in patients with SLE: low erythrocyte CR1 expression is an acquired phenomenon.
Kumar A; Kumar A; Sinha S; Khandekar PS; Banerjee K; Srivastava LM
Immunol Cell Biol; 1995 Oct; 73(5):457-62. PubMed ID: 8595925
[TBL] [Abstract][Full Text] [Related]
15. Low CR1 (C3b receptor) level on erythrocytes is associated with poor prognosis in hemodialysis patients.
Ohi H; Tamano M; Okada N
Nephron Clin Pract; 2008; 108(1):c23-7. PubMed ID: 18075277
[TBL] [Abstract][Full Text] [Related]
16. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Manzi S; Navratil JS; Ruffing MJ; Liu CC; Danchenko N; Nilson SE; Krishnaswami S; King DE; Kao AH; Ahearn JM
Arthritis Rheum; 2004 Nov; 50(11):3596-604. PubMed ID: 15529364
[TBL] [Abstract][Full Text] [Related]
17. Diminished erythropoietin-induced erythroid growth in patients with renal anemia is restored by recombinant human erythroid differentiation factor.
Shimizu T; Kawano Y; Takaue Y; Kuroda Y
Am J Hematol; 1994 Nov; 47(3):178-82. PubMed ID: 7942781
[TBL] [Abstract][Full Text] [Related]
18. Immune complex binding to erythrocyte-CR1 (CD 35), CR1 expression and levels of erythrocyte-fixed C3 fragments in SLE outpatients.
Jepsen HH; Møller Rasmussen J; Teisner B; Schrøder L; Holmskov U; Jarlbaek L; Isager H; Svehag SE
APMIS; 1990 Jul; 98(7):637-44. PubMed ID: 2144431
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus.
Hebert LA; Birmingham DJ; Shen XP; Brandt JT; Sedmak DD; Dillon JJ
Am J Kidney Dis; 1994 Jul; 24(1):25-32. PubMed ID: 8023821
[TBL] [Abstract][Full Text] [Related]
20. A soluble recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes.
Oudin S; Libyh MT; Goossens D; Dervillez X; Philbert F; Réveil B; Bougy F; Tabary T; Rouger P; Klatzmann D; Cohen JH
J Immunol; 2000 Feb; 164(3):1505-13. PubMed ID: 10640768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
